Cancer often comes down to random chance, study says
Lifestyle and heredity get the most blame for cancer, but new research suggests random chance plays a bigger role than people realize.
Diseases
Articles
Eli Lilly chasing psoriasis jackpot with Taltz
Taltz, which hit the market last year, is taking on an armful of older treatments, including creams, lotions, pills and injectables, such as Amgen’s Enbrel and AbbVie’s Humira.
Chinese firm working with Lilly gets positive results on cancer drug
Hutchison China MediTech Ltd., the biotechnology company that has a partnership with Eli Lilly and Co., on Friday reported positive late-stage results for its drug to treat colorectal cancer.
Drug companies willing to spend big in pursuit of Alzheimer’s cure
Alzheimer’s disease is rewriting the rules of drug discovery, with companies like Eli Lilly and others abandoning caution to keep pursuing an elusive hypothesis because the potential payoff is so great.
As pricing criticism mounts, Lilly, other drugmakers roll out pay for performance
In Lilly’s partnership with Harvard Pilgrim Health Care, the not-for-profit insurer gets additional rebates if fewer patients using Lilly's diabetes treatment Trulicity meet blood sugar goals than expected.
Merck stops Alzheimer’s study after ‘no chance’ of benefit
Merck & Co. on Tuesday announced that it will end a study of its once-promising Alzheimer’s disease drug in patients with mild-to-moderate forms of the condition, just three months after Eli Lilly and Co. announced its own setback in a field that’s been littered with failures.
Indy-founded drug firm lands nearly $23M to fight rare disease
Two local men who have been working on a potential blockbuster treatment for a rare and debilitating disease are hopeful that a major injection of venture capital will provide the boost needed to move the drug to market—even if it means sweeping changes for their company.
Lawmakers hear bill to establish ‘hemp oil registry’ for seizure patients
One of the bill’s author said it is designed to help parents who are “up against a wall,” and he stressed that it should not be confused as a first step to medical marijuana legalization in the state.
Lilly shares rise after Alimta cancer drug patent upheld on appeal
Teva Pharmaceuticals Industries Ltd.’s proposed generic version infringes a patent on the multi-billion-dollar patent, the U.S. Court of Appeals for the Federal Circuit ruled.
Carmel biotech firm scores major deal with pharmaceutical giant
A small Carmel-based biotech firm has signed a deal with international drug company Allergan Plc that is worth at least $50 million and could grow to more than $2 billion under the best-case scenario.
After health scare, Carolene Mays-Medley returns to trenches
The executive director at White River State Park is fighting her way back from a ruptured brain aneurysm, a condition that leaves many of its victims disabled, or worse.
Lilly trims profit guidance but says growth strategy on track
The company’s announcement reassured investors in the wake of last month’s news that the Alzheimer’s drug solanezumab had failed to demonstrate effectiveness during a large-scale clinical trial.
My body is the battleground between cancer and chemo
The point of chemo is to cure me. But these are not gentle chemicals. They sweep through my body like a tornado, with side effects that range from annoying to horrendous. But I have no choice.
Tech entrepreneur Don Brown donating $30M to IU School of Medicine
The gift is the largest to the IU School of Medicine by an alumnus. The medical school will use the money to establish the Brown Center for Immunotherapy to fight some of the world’s toughest diseases.
Lilly partners with AstraZeneca on another Alzheimer’s treatment
The Indianapolis-based company, which last month struck out in a late-stage clinical trial for a potential Alzheimer’s drug called solanezumab, announced Friday a collaboration with AstraZeneca to develop another possible treatment for the mind-robbing disease.
Lilly threatens Sanofi’s dominance in insulin with knockoff drug
In a few days, a new type of knockoff medicine will upend a $10 billion diabetes-drug market and exacerbate a brutal price war between some of its biggest players.
After rough November, some good news for Lilly
The FDA says the Indianapolis-based drugmaker and its partner can make an important label claim on its new diabetes drug—a move analysts say could give sales a big boost.
Pharmaceutical firm plans $10.4M in new equipment, 60 jobs
The company has requested a tax break from Indianapolis officials on the project that would save it about $484,000 over eight years.
Lilly competitor to cap price increases as drug costs face more scrutiny
With drug companies under fire, the world’s largest insulin maker plans to limit price increases and introducing a model that ties the cost of medicines to the results they deliver.
Lilly to lay off hundreds after failure of Alzheimer’s drug
Eli Lilly and Co. plans to lay off hundreds of U.S. sales representatives in coming months, following the disappointing failure of an experimental drug for Alzheimer’s disease announced last week.